Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patients

Leuk Lymphoma. 2021 Dec;62(12):3023-3026. doi: 10.1080/10428194.2021.1941930. Epub 2021 Jun 24.

Authors

Marquita Camilleri^{1

2}, Thomas McGrath¹, William Wilson³, Stuart J Ings⁴, Jacqueline Horder¹, Fiona Newrick¹, Jonathan Sive¹, Xenofon Papanikolaou¹, Rakesh Popat^{1

5}, Charalampia Kyriakou¹, Kwee Yong^{1

2}, Neil Rabin¹

Affiliations

¹ Haematology Department, University College Hospitals, , London, UK.
² Cancer Institute, University College London, London, UK.
³ Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.
⁴ Wolfson Cellular Therapy Unit, University College London Hospitals NHS Foundation Trust, London, UK.
⁵ NIHR/UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK.

PMID: 34162310
DOI: 10.1080/10428194.2021.1941930

No abstract available

Publication types

Letter

MeSH terms

Antigens, CD34
COVID-19*
Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cell Transplantation*
Humans
Multiple Myeloma* / therapy
Peripheral Blood Stem Cells*
SARS-CoV-2
Transplantation, Autologous

Substances

Antigens, CD34
Granulocyte Colony-Stimulating Factor